MoonLake Immunotherapeutics (MLTX) Net Income towards Common Stockholders (QoQ) (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) Net Income towards Common Stockholders (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | MoonLake Immunotherapeutics | 1.41 Bn | 1.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.61% |
| Dec 31, 2025 | 10.86% |
| Sep 30, 2025 | -26.12% |
| Jun 30, 2025 | -38.20% |
| Mar 31, 2025 | 12.58% |
| Dec 31, 2024 | -28.47% |
| Sep 30, 2024 | -45.86% |
| Jun 30, 2024 | -77.17% |
| Mar 31, 2024 | -77.18% |
| Dec 31, 2023 | 32.12% |
| Sep 30, 2023 | 5.94% |
| Jun 30, 2023 | -1.10% |
| Mar 31, 2023 | 25.80% |
| Dec 31, 2022 | -11.71% |
| Sep 30, 2022 | 15.36% |
| Jun 30, 2022 | -9.67% |
| Mar 31, 2022 | 70.40% |
| Dec 31, 2021 | -753.10% |
| Sep 30, 2021 | 80.76% |
| Jun 30, 2021 | -42,743.56% |